Atlas Trials

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Clinical trial NCT03305445 · COMPLETED

Trial details

NCT number
NCT03305445
Sponsor
Icahn School of Medicine at Mount Sinai
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Start date
2018-05-14
Primary completion
2021-04-01
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.